They will burn half the cash and the rest will be paid out in...

They will burn half the cash and the rest will be paid out in ridiculous salaries and bonuses.

For those of a charting orientation, the stock is already in overbought territory / but the muppets and naive will probably chase it a bit more before the execs start selling into the strength.

And I’d check your numbers, as I’d be surprised if half the valuation is cash - but just because it is, does not imply that the IP is of equivalent value - because until it passes Phase III clinical trials AND is approved by FDA, it’s basically not worth a razoo!

DDD